250 related articles for article (PubMed ID: 28477490)
1. Characterisation of multifocal breast cancer using the 70-gene signature in clinical low-risk patients enrolled in the EORTC 10041/BIG 03-04 MINDACT trial.
Aalders KC; Kuijer A; Straver ME; Slaets L; Litiere S; Viale G; Van't Veer LJ; Glas AM; Delorenzi M; van Dalen T; Tryfonidis K; Piccart MJ; Cardoso F; Rutgers EJ;
Eur J Cancer; 2017 Jul; 79():98-105. PubMed ID: 28477490
[TBL] [Abstract][Full Text] [Related]
2. 70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age.
Piccart M; van 't Veer LJ; Poncet C; Lopes Cardozo JMN; Delaloge S; Pierga JY; Vuylsteke P; Brain E; Vrijaldenhoven S; Neijenhuis PA; Causeret S; Smilde TJ; Viale G; Glas AM; Delorenzi M; Sotiriou C; Rubio IT; Kümmel S; Zoppoli G; Thompson AM; Matos E; Zaman K; Hilbers F; Fumagalli D; Ravdin P; Knox S; Tryfonidis K; Peric A; Meulemans B; Bogaerts J; Cardoso F; Rutgers EJT
Lancet Oncol; 2021 Apr; 22(4):476-488. PubMed ID: 33721561
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical versus molecular (BluePrint and MammaPrint) subtyping of breast carcinoma. Outcome results from the EORTC 10041/BIG 3-04 MINDACT trial.
Viale G; de Snoo FA; Slaets L; Bogaerts J; van 't Veer L; Rutgers EJ; Piccart-Gebhart MJ; Stork-Sloots L; Glas A; Russo L; Dell'Orto P; Tryfonidis K; Litière S; Cardoso F;
Breast Cancer Res Treat; 2018 Jan; 167(1):123-131. PubMed ID: 28929359
[TBL] [Abstract][Full Text] [Related]
4. Additional prognostic value of the 70-gene signature (MammaPrint(®)) among breast cancer patients with 4-9 positive lymph nodes.
Saghatchian M; Mook S; Pruneri G; Viale G; Glas AM; Guerin S; Cardoso F; Piccart M; Tursz T; Delaloge S; van't Veer L
Breast; 2013 Oct; 22(5):682-90. PubMed ID: 23347730
[TBL] [Abstract][Full Text] [Related]
5. Multicentric and multifocal versus unifocal breast cancer: is the tumor-node-metastasis classification justified?
Weissenbacher TM; Zschage M; Janni W; Jeschke U; Dimpfl T; Mayr D; Rack B; Schindlbeck C; Friese K; Dian D
Breast Cancer Res Treat; 2010 Jul; 122(1):27-34. PubMed ID: 20454925
[TBL] [Abstract][Full Text] [Related]
6. Metastatic potential of T1 breast cancer can be predicted by the 70-gene MammaPrint signature.
Mook S; Knauer M; Bueno-de-Mesquita JM; Retel VP; Wesseling J; Linn SC; Van't Veer LJ; Rutgers EJ
Ann Surg Oncol; 2010 May; 17(5):1406-13. PubMed ID: 20094918
[TBL] [Abstract][Full Text] [Related]
7. [Prognostic value of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in node positive breast cancer patients treated by mastectomy].
Wang SL; Li YX; Song YW; Wang WH; Jin J; Liu YP; Liu XF; Yu ZH
Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):520-5. PubMed ID: 21029696
[TBL] [Abstract][Full Text] [Related]
8. An association study of established breast cancer reproductive and lifestyle risk factors with tumour subtype defined by the prognostic 70-gene expression signature (MammaPrint
Makama M; Drukker CA; Rutgers EJT; Slaets L; Cardoso F; Rookus MA; Tryfonidis K; Van't Veer LJ; Schmidt MK
Eur J Cancer; 2017 Apr; 75():5-13. PubMed ID: 28214658
[TBL] [Abstract][Full Text] [Related]
9. Prospective Validation of a Genomic Assay in Breast Cancer: The 70-gene MammaPrint Assay and the MINDACT Trial.
Audeh W; Blumencranz L; Kling H; Trivedi H; Srkalovic G
Acta Med Acad; 2019 Apr; 48(1):18-34. PubMed ID: 31264430
[TBL] [Abstract][Full Text] [Related]
10. Axillary lymph node status and prognosis in multifocal and multicentric breast carcinoma.
Duraker N; Caynak ZC
Breast J; 2014; 20(1):61-8. PubMed ID: 24438065
[TBL] [Abstract][Full Text] [Related]
11. The importance of multifocal/multicentric tumor on the disease-free survival of breast cancer patients: single center experience.
Ustaalioglu BO; Bilici A; Kefeli U; Şeker M; Oncel M; Gezen C; Gumus M; Demirelli F
Am J Clin Oncol; 2012 Dec; 35(6):580-6. PubMed ID: 21926901
[TBL] [Abstract][Full Text] [Related]
12. Pathologic analysis of tumor size and lymph node status in multifocal/multicentric breast carcinoma.
Andea AA; Wallis T; Newman LA; Bouwman D; Dey J; Visscher DW
Cancer; 2002 Mar; 94(5):1383-90. PubMed ID: 11920492
[TBL] [Abstract][Full Text] [Related]
13. Estrogen receptor, Progesterone receptor, HER2 status and Ki67 index and responsiveness to adjuvant tamoxifen in postmenopausal high-risk breast cancer patients enrolled in the DBCG 77C trial.
Knoop AS; Lænkholm AV; Jensen MB; Nielsen KV; Andersen J; Nielsen D; Ejlertsen B;
Eur J Cancer; 2014 May; 50(8):1412-21. PubMed ID: 24675287
[TBL] [Abstract][Full Text] [Related]
14. Gene expression profiling to predict the risk of locoregional recurrence in breast cancer: a pooled analysis.
Drukker CA; Elias SG; Nijenhuis MV; Wesseling J; Bartelink H; Elkhuizen P; Fowble B; Whitworth PW; Patel RR; de Snoo FA; van 't Veer LJ; Beitsch PD; Rutgers EJ
Breast Cancer Res Treat; 2014 Dec; 148(3):599-613. PubMed ID: 25414025
[TBL] [Abstract][Full Text] [Related]
15. [Clinicopathological features and prognostic factors of breast cancer patients with inguinal lymph node metastases: a report of 17 cases].
Li Q; Xu BH; Zhang P; Li Q; Yuan P; Wang JY; Luo Y; Ma F; Fan Y; Li Q
Zhonghua Zhong Liu Za Zhi; 2013 Mar; 35(3):207-11. PubMed ID: 23880002
[TBL] [Abstract][Full Text] [Related]
16. Risk estimation of distant metastasis in node-negative, estrogen receptor-positive breast cancer patients using an RT-PCR based prognostic expression signature.
Tutt A; Wang A; Rowland C; Gillett C; Lau K; Chew K; Dai H; Kwok S; Ryder K; Shu H; Springall R; Cane P; McCallie B; Kam-Morgan L; Anderson S; Buerger H; Gray J; Bennington J; Esserman L; Hastie T; Broder S; Sninsky J; Brandt B; Waldman F
BMC Cancer; 2008 Nov; 8():339. PubMed ID: 19025599
[TBL] [Abstract][Full Text] [Related]
17. Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy.
Esteva FJ; Sahin AA; Cristofanilli M; Coombes K; Lee SJ; Baker J; Cronin M; Walker M; Watson D; Shak S; Hortobagyi GN
Clin Cancer Res; 2005 May; 11(9):3315-9. PubMed ID: 15867229
[TBL] [Abstract][Full Text] [Related]
18. 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer.
Cardoso F; van't Veer LJ; Bogaerts J; Slaets L; Viale G; Delaloge S; Pierga JY; Brain E; Causeret S; DeLorenzi M; Glas AM; Golfinopoulos V; Goulioti T; Knox S; Matos E; Meulemans B; Neijenhuis PA; Nitz U; Passalacqua R; Ravdin P; Rubio IT; Saghatchian M; Smilde TJ; Sotiriou C; Stork L; Straehle C; Thomas G; Thompson AM; van der Hoeven JM; Vuylsteke P; Bernards R; Tryfonidis K; Rutgers E; Piccart M;
N Engl J Med; 2016 Aug; 375(8):717-29. PubMed ID: 27557300
[TBL] [Abstract][Full Text] [Related]
19. Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER).
Bueno-de-Mesquita JM; van Harten WH; Retel VP; van 't Veer LJ; van Dam FS; Karsenberg K; Douma KF; van Tinteren H; Peterse JL; Wesseling J; Wu TS; Atsma D; Rutgers EJ; Brink G; Floore AN; Glas AM; Roumen RM; Bellot FE; van Krimpen C; Rodenhuis S; van de Vijver MJ; Linn SC
Lancet Oncol; 2007 Dec; 8(12):1079-1087. PubMed ID: 18042430
[TBL] [Abstract][Full Text] [Related]
20. Relative effectiveness of adjuvant chemotherapy for invasive lobular compared with invasive ductal carcinoma of the breast.
Marmor S; Hui JYC; Huang JL; Kizy S; Beckwith H; Blaes AH; Rueth NM; Tuttle TM
Cancer; 2017 Aug; 123(16):3015-3021. PubMed ID: 28382636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
